Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c

Audentes Therapeutics (NASDAQ: BOLD) reported Q2 EPS of ($0.85), $0.07 worse than the analyst estimate of ($0.78).

"We're very pleased with continued clinical progress in ASPIRO, and in particular the results of the muscle biopsy data from the first three ASPIRO patients, which show unprecedented levels of tissue transduction and protein expression from a systemically administered gene therapy for a neuromuscular disease," stated Dr. Suyash Prasad, Senior Vice President and Chief Medical Officer of Audentes. "The consistency of effect between the functional measures and histological improvement gives us further confidence in the emerging profile of AT132 as a therapy with the potential to bring transformative benefit to patients living with XLMTM. We look forward to continuing with the per protocol dose escalation and initiating enrollment of the second dose cohort at the 3x1014 vg/kg dose in the coming weeks."

"We anticipate building on the significant momentum of our XLMTM program with continued progress across our portfolio of product candidates, including advancing an exciting new research initiative directed toward a large neuromuscular disease with significant unmet medical need," stated Matthew R. Patterson, Chief Executive Officer of Audentes. "Coupled with further advancements in the commercial readiness of our manufacturing operations, we believe we are well-positioned as a leader in the AAV gene therapy field with significant near-term growth potential."

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Robert Half International (RHI) Reports In-Line Q1 EPS
• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend